Tirzepatide (brand name Mounjaro) : Received FDA approval in May 2022, this is a dual GIP and GLP-1 receptor agonist indicating a novel class of drugs offering significant improvements in glycemic control and weight reduction
11 While a number of different non-medication options exist for treatment of OSA, including lifestyle modifications, breathing devices, oral appliances, and surgical procedures, tirzepatide was approved by the FDA for moderate to severe obstructive sleep apnea in late 2024
The time course of muscle mass loss generally parallels the rate of weight loss, with the most rapid changes occurring in the first 34 months of treatment, particularly with higher-dose agents such as semaglutide and tirzepatide
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
It converts into active d-amphetamine in your body and helps boost dopamine and norepinephrine
Prior to that approval, Novo Nordisk, which also makes the injectable semaglutide drugs Ozempic and Wegovy, had seen promising results from its trials of the weight-loss pill, which will also be sold under the brand name Wegovy